Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, plac...
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
ObjectiveTo assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS).MethodsThis phase III, randomised, double-blind, placebo-controlled study enrolled patients aged ≥18 years diagnosed with active AS, meeting the modified New York criteria, with centrally read radiographs, and an inadequate response or in...
Alternative Titles
Full title
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8292568
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8292568
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2020-219601
